Ranbaxy plans Rs 200-cr dosage facility
Ranbaxy is planning to set up a new dosage manufacturing facility to cater to the emerging and non-regulated markets.
By Khomba Singh, TNN |
NEW DELHI: India’s largest drug maker Ranbaxy is planning to set up a new dosage manufacturing facility to cater to the emerging and non-regulated markets. The company is expected to invest a “couple of hundred crores” in the high capacity plant that will be developed in two phases, a Ranbaxy insider said on condition of anonymity.
One of the possible sites for the unit is the company’s proposed special economic zone in Mohali. However, details regarding the location, capacity and investment will be finalised only by the end of the year, sources said. The Ranbaxy spokesperson was not available for comment. At present, Ranbaxy has over 10 manufacturing centres in the country.
Dosage forms are mostly manufactured at its Ponta Sahib (Himachal Pradesh) and Dewasir (Madhya Pradesh) plants. While Ponta Sahib plant has almost reached its capacity, there is limited room for expansion in its Dewasir unit.
The new dosage facility will be US Foods and Drugs Administration (USFDA) approved and will supply products globally. When it gets operational, Ranbaxy will be able to meet its worldwide product supply for the next 3-5 years.
The company is planning to launch 400-500 new products in 30-40 emerging and non-regulated markets every year. Of late, the growth of Ranbaxy which has presence over 100 countries, is largely driven by emerging markets—locations that were mostly ignored by the company just three years ago, where the number of new product launches was just about half of what the company now targets. Today, after a spate of takeovers, Ranbaxy has a balanced mix of revenues from developed, emerging and domestic markets.
In the US—where India’s pharma biggies made their fortune before cut-throat competition from Chinese as well as next-generation Indian players forced them to look beyond—Ranbaxy plans to launch around 20-25 products every year, with focus on speciality and niche products.
The company is also planning to leverage its existing facilities spread across 11 countries. Ranbaxy plans to shift manufacturing of some of its products from its overseas facilities to India and vice versa, depending upon the requirements and convenience. For example, the company plans to start manufacturing some antibiotics and statins in the Betapaharm facility in Romania.
One of the possible sites for the unit is the company’s proposed special economic zone in Mohali. However, details regarding the location, capacity and investment will be finalised only by the end of the year, sources said. The Ranbaxy spokesperson was not available for comment. At present, Ranbaxy has over 10 manufacturing centres in the country.
Dosage forms are mostly manufactured at its Ponta Sahib (Himachal Pradesh) and Dewasir (Madhya Pradesh) plants. While Ponta Sahib plant has almost reached its capacity, there is limited room for expansion in its Dewasir unit.
The new dosage facility will be US Foods and Drugs Administration (USFDA) approved and will supply products globally. When it gets operational, Ranbaxy will be able to meet its worldwide product supply for the next 3-5 years.
The company is planning to launch 400-500 new products in 30-40 emerging and non-regulated markets every year. Of late, the growth of Ranbaxy which has presence over 100 countries, is largely driven by emerging markets—locations that were mostly ignored by the company just three years ago, where the number of new product launches was just about half of what the company now targets. Today, after a spate of takeovers, Ranbaxy has a balanced mix of revenues from developed, emerging and domestic markets.
In the US—where India’s pharma biggies made their fortune before cut-throat competition from Chinese as well as next-generation Indian players forced them to look beyond—Ranbaxy plans to launch around 20-25 products every year, with focus on speciality and niche products.
ADVERTISEMENT
The company is also planning to leverage its existing facilities spread across 11 countries. Ranbaxy plans to shift manufacturing of some of its products from its overseas facilities to India and vice versa, depending upon the requirements and convenience. For example, the company plans to start manufacturing some antibiotics and statins in the Betapaharm facility in Romania.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
